Characterization of STAT5B phosphorylation correlating with expression of cytokine-inducible SH2-containing protein (CIS).
Cytokine-inducible SH2-containing protein (CIS) is the first identified member of genes encoding for the suppressor of cytokine signaling (SOCS). CIS is also a well-known target gene of signal transducer and activator of transcription 5 (STAT5) pathways, providing normal negative feedback control of signaling by cytokines and growth factors. Three other SOCS genes, SOCS1, SOCS2, and SOCS3, can be silenced by DNA hypermethylation in human cancers, suggesting a potential mechanism for constitutive STAT activation. However, it is not known whether CIS expression is similarly perturbed in tumor cells. We report here the absence of CIS expression in T lymphoma LSTRA that overexpresses the Lck protein tyrosine kinase and exhibits elevated STAT5 activity. Pervanadate-induced CIS expression and STAT5 binding to the CIS promoter in vivo over a short time course implies that mechanisms other than DNA hypermethylation may contribute to defective CIS expression in LSTRA cells. Comparison with cytokine-dependent BaF3 cells stimulated with interleukin-3 (IL-3) further reveals that CIS induction correlates with specific STAT5b post-translational modifications. It exhibits as the slowest migrating form through SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. This distinctly modified STAT5b is the predominant form that binds to the consensus STAT5 sites in the CIS promoter and accumulates in the nucleus. In vitro phosphatase assays and phosphoamino acid analysis suggest the involvement of phosphorylation on residues other than the highly conserved tyrosine and serine sites in this distinct STAT5b mobility shift. All together, our results provide a novel link between incomplete STAT5b phosphorylation and defective SOCS gene expression in cancer cells.
Cooper
John C
JC
Department of Molecular Physiology and Biophysics, Room 813B Light Hall, Vanderbilt University School of Medicine, Nashville, TN 37232-0615, USA.
Boustead
Jared N
JN
Yu
Chao-Lan
CL
D000818:Animals; D002460:Cell Line; D002467:Cell Nucleus / Q000737:chemistry; D002478:Cells, Cultured; D024202:Electrophoretic Mobility Shift Assay; D017874:Immediate-Early Proteins / Q000235:genetics / Q000378:metabolism*; D007377:Interleukin-3 / Q000494:pharmacology; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Q000378:metabolism; D051379:Mice; D008958:Models, Molecular; D010766:Phosphorylation; D011401:Promoter Regions, Genetic; D011499:Protein Processing, Post-Translational; D050799:STAT5 Transcription Factor / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D012694:Serine / Q000737:chemistry / Q000235:genetics; D050826:Suppressor of Cytokine Signaling Proteins; D013601:T-Lymphocytes / Q000166:cytology; D014443:Tyrosine / Q000737:chemistry / Q000235:genetics; D014638:Vanadates / Q000494:pharmacology
D017874:Immediate-Early Proteins; D007377:Interleukin-3; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck); D050799:STAT5 Transcription Factor; D012694:Serine; D050826:Suppressor of Cytokine Signaling Proteins; D014443:Tyrosine; D014638:Vanadates